• Wed. Jun 7th, 2023

FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Wellness


May 26, 2023

Supporting FivepHusion’s Worldwide Improvement and Commercialization Technique

SYDNEY, May well 26, 2023 /PRNewswire/ — FivepHusion, an sophisticated clinical-stage biotechnology firm, now announced its collaboration with Treehill Partners, a New York-primarily based strategic and monetary advisory firm specializing in healthcare market transactions, and Syneos Health® (Nasdaq: SYNH), a major totally integrated biopharmaceutical options organization, to create and bring a novel, enhanced chemotherapeutic solution to marketplace.

Treehill Partners will assistance FivepHusion with integrated small business improvement, operational, strategic and transactional experience. Syneos Wellness will assistance FivepHusion’s integrated clinical improvement and commercialization capabilities. This collaboration is made to strategically and optimally progress improvement and commercialization of FivepHusion’s enhanced chemotherapeutic formulation Deflexifol™ in international markets.

“This is a really fascinating time for FivepHusion. We are at a important stage in our development method. By collaborating with Treehill Partners and Syneos Wellness, we think we are positioned to effectively bring our improvement operate on Deflexifol™ to international markets, like in the US, Europe and Asia,” mentioned Dr. Christian Toouli, CEO &amp Managing Director, FivepHusion. “This collaboration represents a exceptional functioning model to the market. Via the combined strength and competency of 3 market leaders, we intend to maximize our progress on the improvement of Deflexifol™ and swiftly bring revolutionary oncology medicines to individuals in require.”

“We’re excited to collaborate with FivepHusion and Treehill Partners to aid bring Deflexifol™ to individuals,” mentioned Christian Tucat, Chief Small business Officer, Syneos Wellness. “Leveraging our deep therapeutic and international experience, Syneos Wellness is pleased to contribute to accelerating the clinical improvement and commercialization of this critical new therapy.”

Story continues

“This collaboration represents a new model of integrated solutions across disciplines, made to permit US and non-US emerging players to play a important function on the international stage, and we’re proud to operate alongside FivepHusion and Syneos Wellness,” mentioned Ali Pashazadeh, Companion &amp Co-founder, Treehill Partners. “By merging the scientific prowess of our clientele with the clinical and industrial experience of Syneos Wellness and Treehill’s healthcare advisory and execution capabilities, we are offering a exceptional ecosystem made to aid corporations to flourish in spite of the existing difficult marketplace atmosphere.”

About FivepHusion

FivepHusion (www.fivephusion.com) is an sophisticated clinical-stage, globally focused biotechnology firm whose goal is to optimize chemotherapy to increase patient remedy outcomes and high-quality of life.

FivepHusion is establishing Deflexifol™, a proprietary, novel, and optimized physiological pH formulation to co-administer the chemotherapeutic agent five-fluorouracil (five-FU) and its biomodulator leucovorin (LV), a drug that enhances five-FU anti-cancer activity. These drugs are generally employed globally to treat many strong tumors like colorectal, pancreatic, gastric and breast cancers. Even so, due to their chemical incompatibility, existing formulations of five-FU and LV endure from limitations in their security, tolerability, effectiveness and pharmacological compatibility. These disadvantages contribute to restricted remedy response prices, unpleasant side effects and toxicities, and a decreased high-quality of life skilled by cancer individuals. Deflexifol™ has been made to address these limitations by means of co-administration of the two agents with clinically demonstrated improvements in security and tolerability and the possible to present superior anti-tumor efficacy, much better high-quality of life, and general enhanced clinical advantage for cancer individuals.

FivepHusion is establishing Deflexifol™ by means of the FDA 505(b)(two) and EMA Write-up 10b regulatory pathways as a bioequivalent, chemotherapy replacement of sub-optimal typical of care formulations of five-FU and LV for the remedy of metastatic colorectal cancer, and other tumors with a projected international incidence of higher than six million individuals. Deflexifol™ is also getting created as a new therapy for cancers with higher unmet healthcare require, like pediatric ependymoma a uncommon and deadly brain cancer which afflicts really young youngsters.

Deflexifol™ is a trademark of FivepHusion.

About Syneos Wellness

Syneos Health® (Nasdaq: SYNH) is a major totally integrated biopharmaceutical options organization constructed to accelerate consumer results.  Syneos translates exceptional clinical, healthcare affairs and industrial insights into outcomes to address modern day marketplace realities.

Syneos brings with each other a talented group of pros, who operate across much more than 110 nations, with a deep understanding of patient and doctor behaviors and marketplace dynamics. Collectively Syneos shares insights, makes use of the most recent technologies and applies sophisticated small business practices to speed customers’ delivery of critical therapies to individuals.

Syneos Wellness supports a diverse, equitable and inclusive culture that cares for colleagues, consumers, individuals, communities and the atmosphere.

To study much more about how Syneos are Shortening the distance from lab to life®, go to syneoshealth.com or subscribe to our podcast.

About Treehill Partners

Treehill was founded in 2014 and is led by companion and co-founder Ali Pashazadeh, who previously headed Blackstone’s healthcare advisory group and UBS’ European biotech coverage.

Treehill supports clientele in the healthcare market all through the asset lifecycle, from purchase-side acquisition and investment more than worth develop and development to sell-side disposal and divestment. Important locations of concentrate are the identifying and executing of worth inventive transactions and their knitting into prosperous corporate evolution approaches.

In delivering its assistance, the firm employs a multidisciplinary senior group with impeccable pedigree that comprises healthcare physicians/ MDs, scientists/ PhDs, CEOs of biotechs, senior executives from big pharma, and skilled method consultants and investment bankers. Solutions supplied are centered about the “principal mentality” of the group, delivering actionable strategic and transaction assistance that matters to CEOs, senior leadership, their stakeholders and investors.



View original content material to download multimedia:https://www.prnewswire.com/news-releases/fivephusion-announces-strategic-collaboration-with-treehill-partners-and-syneos-well being-301835410.html

Supply FivepHusion

Leave a Reply